Supplementary Methods from Temozolomide Does Not Impair Gene Therapy-Mediated Antitumor Immunity in Syngeneic Brain Tumor Models

Marianela Candolfi(Universidad de Buenos Aires), María G. Castro(University of Michigan)

Unknown

March 31, 2023

10.1158/1078-0432.22450926.v1

Cited by 0

Related Papers

HMGB1 Mediates Endogenous TLR2 Activation and Brain Tumor Regression

|PLoS Medicine|2009|366

Mechanisms of Glioma Formation: Iterative Perivascular Glioma Growth and Invasion Leads to Tumor Progression, VEGF-Independent Vascularization, and Resistance to Antiangiogenic Therapy

|Neoplasia|2014|155

Combined Immunostimulation and Conditional Cytotoxic Gene Therapy Provide Long-term Survival in a Large Glioma Model

|Cancer Research|2005|127

G-CSF secreted by mutant IDH1 glioma stem cells abolishes myeloid cell immunosuppression and enhances the efficacy of immunotherapy

|Science Advances|2021|90

Plasmacytoid Dendritic Cells in the Tumor Microenvironment: Immune Targets for Glioma Therapeutics

|Neoplasia|2012|62